Novartis AG Interest Expense 2011-2026 | NVS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Novartis AG

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.14 B	1.01 B	855 M	800 M	787 M	869 M	850 M	932 M	750 M	707 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.14 B	707 M	870 M

Quarterly Interest Expense Novartis AG

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	202 M	-	-	-	201 M	-	-	-	220 M	-	-	-	205 M	-	-	-	237 M	-	-	-	192 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
237 M	192 M	210 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Altimmune ALT	-190 K	$ 3.45	3.29 %	$ 304 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 19.55	0.26 %	$ 914 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Autolus Therapeutics plc AUTL	9.29 M	$ 1.4	1.82 %	$ 357 M	Britain
Ascendis Pharma A/S ASND	80.6 M	$ 218.41	-1.57 %	$ 5 B	Danmark
Aytu BioScience AYTU	-512 K	$ 2.61	-	$ 16.4 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Benitec Biopharma BNTC	-126 K	$ 11.01	0.27 %	$ 453 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Compugen Ltd. CGEN	281 K	$ 2.08	-0.48 %	$ 194 M	Israel
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Coherus BioSciences CHRS	9 M	$ 1.59	4.28 %	$ 186 M	USA
Cellectis S.A. CLLS	371 K	$ 3.37	0.75 %	$ 116 M	France
Cullinan Management CGEM	-443 K	$ 12.91	1.33 %	$ 778 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
CorMedix CRMD	34.3 K	$ 6.32	1.12 %	$ 455 K	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Clovis Oncology CLVS	444 K	-	-7.23 %	$ 13 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.26	0.35 %	$ 707 M	Canada
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA